In a recent column for Clinical Leader, Dicot Pharma CEO Elin Trampe discussed how clinical milestones, financing strategy, shareholder value, and partnering considerations must be tightly integrated in early development through late-stage planning.

She also outlined how maintaining scientific rigour while building long-term commercial value shapes trial design, investor communication, and licensing timing in a competitive biotech landscape.

The full article can be accessed here.